En Es
Categories

Industry News


Randox and Bosch Partner to Launch Molecular Diagnostics Platform

By Labmedica International staff writers
01 Mar 2018

Image: The Vivalytic all-in-one fully automated solution for molecular diagnostics (Photo courtesy of Randox Laboratories and Bosch Healthcare Solutions).Global healthcare diagnostics manufacturer Randox Laboratories (Crumlin, Northern Ireland, UK) has partnered with Bosch Healthcare Solutions GmbH (Waiblingen, Germany) to launch Vivalytic, an all-in-one fully automated solution for molecular diagnostics.

Randox develops, manufactures and markets diagnostic reagents and equipment for laboratory medicine. Its range of products includes Biochip Array Technology, clinical chemistry analyzers and reagents, quality control materials and schemes and an extensive life science portfolio. The company’s products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories.

Bosch Healthcare Solutions GmbH, a wholly owned subsidiary of Robert Bosch GmbH, develops products and services to improve people’s health and quality of life. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

Vivalytic combines the broadest range of test options and uses Randox-patented Biochip Array Technology, making it the easiest to use and most comprehensive multiplex PCR platform in the market. The device also supports single-plex and low-plex testing, simplifying the processes for otherwise complex laboratory test procedures. Depending upon the test application, Vivalytic delivers results from 30 minutes.

The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually transmitted infections. The Respiratory Multiplex Array simultaneously detects 22 viral and bacterial pathogens, including Bordetella parapertussis, without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 viral, bacterial and protozoan STIs from a single urine or urogenital swab sample.

“This is transformational for patients and doctors; never before has there been this level of accessibility to such a wealth of molecular tests. Randox molecular assays continue to evolve, keeping precise diagnostics for targeted patient therapy at the centre. With Vivalytic, there’s no limit to the testing portfolio that can be made available on its universal platform, and importantly it delivers results quickly and accurately,” said Dr Peter FitzGerald, MD of Randox Laboratories.

“This is an ideal partnership for Randox, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. With antibiotic resistance one of the most pressing public health issues faced across the world today, we’re delighted that the first tests available on Vivalytic are our industry-leading multiplex panels for respiratory and sexually transmitted infections. This Randox-Bosch partnership enables quick, accurate diagnosis, improved patient care and the effective stewardship of critical medicines.”

“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients,” said Marc Meier, General Manager of Bosch Healthcare Solutions. “In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”



E-mail Print
FaceBook Twitter Google+ Linked in

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmaceutical companies and veterinary clinics, including clinical chemistry and immunoassay analysers, high quality reagents, and quality control material.
Gold member
More info

More articles about Randox Laboratories

28 Oct 2020
Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership
The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory settings for rapidly detecting COVID-19.
Read More

Additional news

26 Jul 2021
GE Healthcare Backs Development of Innovative Total-Body PET/CT Scanner for Simultaneous Whole-Body Imaging
GE Healthcare (Chicago, IL, USA) is backing a collaboration among Quibim (Valenciana, Spain), Full Body Insight, and Oncovision (Valenciana, Spain) to build an innovative total-body PET/CT scanner for simultaneous whole-body imaging.
Read More
23 Jul 2021
RSNA 2021 to Be In-Person Event with Demonstrations of Latest Medical Imaging Technologies in CT, MRI and AI
The world's largest radiology forum is all set to offer robust in-person scientific assembly and technical exhibition with demonstrations of the latest medical imaging technologies in CT, MRI, artificial intelligence (AI), 3D printing and more.
Read More
21 Jul 2021
BD Seeks to Transform Patient Experience Through Vision of 'One-Stick Hospital Stay'
Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history of innovation and leadership in blood collection and vascular access solutions.
Read More
19 Jul 2021
ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC
ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders.
Read More
16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More
14 Jul 2021
Global Smart Hospitals Market to Reach USD 221.3 Billion by 2030 Due to Proliferation of ML, AI and IoT
The global smart hospitals market is expected to reach USD 221.3 billion by the end of 2030 due to health professionals increasing their usage of electronic health records and connected medical assistance.
Read More
13 Jul 2021
AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms
Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyze Computed Tomography (CT) scans in just seconds.
Read More
13 Jul 2021
Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.
Read More
08 Jul 2021
Global AI-Based Surgical Robots Market to Reach USD 17.2 Billion by 2028
The global AI-based surgical robots market size is expected to expand at a CAGR of 17.2% from 2021 to 2028 to reach USD 17.2 billion by 2028, driven by increased efficiency and success rate offered by robotic surgeries, along with a shift in the preference for minimally invasive surgeries by patients over traditional methods.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions